Insider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 74,321 Shares of Stock
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 74,321 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $30.14, for a total transaction of $2,240,034.94. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of ACADIA Pharmaceuticals Inc. (ACAD) traded down $0.73 during trading on Thursday, reaching $28.78. 2,744,200 shares of the company’s stock traded hands, compared to its average volume of 1,350,000. The company has a market cap of $3,520.00, a price-to-earnings ratio of -11.70 and a beta of 3.79. ACADIA Pharmaceuticals Inc. has a 12-month low of $25.06 and a 12-month high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.10. The firm had revenue of $35.58 million for the quarter, compared to analyst estimates of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The business’s revenue for the quarter was up 571.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.61) EPS. analysts expect that ACADIA Pharmaceuticals Inc. will post -2.41 earnings per share for the current fiscal year.
ACAD has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 5th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $50.00 target price (up previously from $48.00) on shares of ACADIA Pharmaceuticals in a research report on Monday, October 2nd. Needham & Company LLC reissued a “buy” rating and issued a $49.00 price target on shares of ACADIA Pharmaceuticals in a report on Sunday, September 17th. JPMorgan Chase & Co. set a $50.00 price target on shares of ACADIA Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 5th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $61.00 price target (up previously from $54.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $48.86.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/04/insider-selling-acadia-pharmaceuticals-inc-acad-evp-sells-74321-shares-of-stock.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.